RxDoctor Payments Data

Michael Shaw

Psychiatric/Mental Health · Brandon, MSNPI 1073058020

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 61 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$307
  • Teva Pharmaceuticals USA, Inc.$235
  • Johnson & Johnson$208
  • Lundbeck LLC$160
  • Neurocrine Biosciences, Inc.$150
  • Vanda Pharmaceuticals Inc.$134
  • plus $331 from 7 others

What the payments were for

  • Food & beverage$1,43194%
  • Education$946%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,526 in reported general payments places this provider in the 65th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,577
Medicare patients
31
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$64,693
TrintellixVortioxetine Hydrobromide19$10,239
Aripiprazole93$3,059
Haloperidol43$1,350
Haloperidol Decanoate30$1,159
Divalproex Sodium ErDivalproex Sodium31$1,096
Hydroxyzine Pamoate66$942
Buspirone Hcl42$873
Benztropine Mesylate85$833
Lurasidone Hcl18$655
Venlafaxine Hcl ErVenlafaxine Hcl31$536
Risperidone54$522
Atomoxetine Hcl14$517
Trihexyphenidyl Hcl43$489
Duloxetine Hcl52$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$208$64,69319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Brandon

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →